TELESIS BIO (TBIO)
(Delayed Data from NSDQ)
$3.57 USD
+0.48 (15.53%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $3.66 +0.09 (2.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.57 USD
+0.48 (15.53%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $3.66 +0.09 (2.52%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Cytokinetics (CYTK) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Cytokinetics (CYTK) delivered earnings and revenue surprises of -33.98% and 82.48%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Janux Therapeutics, Inc. (JANX) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Janux Therapeutics, Inc. (JANX) delivered earnings and revenue surprises of 19.23% and 15.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Telesis Bio (TBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Telesis Bio (TBIO) delivered earnings and revenue surprises of 2.63% and 14.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Emergent Biosolutions (EBS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -89.82% and 15.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Beat the Market the Zacks Way: Hershey's, Telesis Bio, General Mills in Focus
by Abhinab Dasgupta
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Telesis Bio (TBIO) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Telesis Bio (TBIO) delivered earnings and revenue surprises of 12.50% and 5.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Paratek Pharmaceuticals (PRTK) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Paratek (PRTK) delivered earnings and revenue surprises of -1,300% and 33.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Telesis Bio (TBIO) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Evogene (EVGN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Evogene (EVGN) delivered earnings and revenue surprises of 66.67% and 20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Acadia Pharmaceuticals (ACAD) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Acadia (ACAD) delivered earnings and revenue surprises of -4% and 1.55%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should First Trust Small Cap Growth AlphaDEX ETF (FYC) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for FYC
Sanofi (SNY) Skin Disorder Drug Misses Goal in Phase III Study
by Zacks Equity Research
Sanofi's (SNY) rilzabrutinib fails to meet the primary endpoint in a phase III study. It was added to its portfolio following the acquisition of Principia Biopharma last year.
Sanofi (SNY) to Buy Kadmon for $1.9B, Add cGVHD Drug Rezurock
by Zacks Equity Research
Sanofi (SNY) offers $1.9 billion to buy Kadmon Holdings to strengthen its transplant business.
Delta Variant Surge Brings Biotech ETFs in Focus
by Sweta Jaiswal, FRM
The biotech sector seems like a lucrative investment space as the delta variant of coronavirus continues to spread.
Will Translate Bio, Inc. (TBIO) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Genocea (GNCA) Begins Phase I/IIa Study for Solid Tumor Drug
by Zacks Equity Research
Genocea Biosciences (GNCA) doses the first patient in phase I/IIa study on its investigational neoantigen-targeted T-Cell therapy, GEN-011, for solid tumors
Sanofi (SNY)/Translate Bio Begin Study on mRNA Flu Vaccine
by Zacks Equity Research
Sanofi (SNY) and Translate Bio begin a phase I study on an mRNA-based vaccine candidate against seasonal influenza.
Sanofi (SNY) Stops Venglustat Development as Kidney Cyst Drug
by Zacks Equity Research
Sanofi (SNY) discontinues development of pipeline candidate, venglustat, in patients with autosomal dominant polycystic kidney disease, following failure in a pivotal study.
Sanofi/Glaxo Initiate Pivotal Global COVID-19 Vaccine Study
by Zacks Equity Research
Sanofi (SNY) and Glaxo initiate phase III study to evaluate their adjuvanted COVID-19 vaccine candidate. A booster program will start soon.
Sanofi (SNY) to Start Phase III COVID-19 Vaccine Study Soon
by Zacks Equity Research
Based on promising interim data from a phase II study, Sanofi (SNY) plans to initiate a pivotal late-stage study on its adjuvanted vaccine candidate being developed in collaboration with Glaxo in the coming weeks.
Translate Bio, Inc. (TBIO) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Translate Bio, Inc. (TBIO) delivered earnings and revenue surprises of -11.11% and -12.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Best Biotech Stocks & ETFs for mRNA, Gene Editing
by Neena Mishra
Here is what you should know about investing in these life changing technologies.
Will Translate Bio, Inc. (TBIO) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Translate Bio, Inc. (TBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sanofi (SNY) Q1 Earnings & Sales Beat, Keeps 2021 EPS View
by Zacks Equity Research
Sanofi's (SNY) Q1 earnings and sales beat estimates. Dupixent drives sales growth in the quarter.